The strategy is to obtain pain mechanism related date from patients using bio-marker together with clinical measures to qualify go/no-go decisions and to be optimally qualified for selecting patients for later clinical trials, i.e selecting the most optimal primary outcome parameters. Such studies can be done for single dose, multiple dosing or in dose escalation studies. Adding experimental tests measures in such studies are for free at they can be done in addition to sampling the clinical efficacy data.
Working with CCBR speeds up and drives efficiencies in clinical trials by offering greater numbers of patients across fewer sites
A Global Footprint covering 16 dedicated Clinical Research Centers in high density population areas
Uniform SOPs enable the tightest possible adherence to study protocols and consistency across all CCBR sites
Real-Time tacking of subject enrolment and trial progress ensures sponsors have the most up to date information, all of the time
Centralised, standardised billing affords better visibility into trial costs for sponsors
